Novartis Ag

Irm LLC

Ha-Soon Choi

Bao Vinh Nguyen

Hank Michael James Petrassi

James Paul Lajiness

Zhicheng Wang

Srinivasa Reddy Natala

Jiqing Jiang

Yun He

Xiaohui He

Baogen Wu

Kunyong Yang

Nathanael Schiander Gray

Yi Liu

Pingda Ren

Pamela Ann Albaugh

Tao Jiang

Truc Ngoc Nguyen

Guobao Zhang

Yongping Xie

Hong Liu

Paul Vincent Rucker

Yi Fan

Taebo Sim

Xia Wang

Gregory B Chopiuk

Barun Okram

David Archer Ellis

Victor Ivanovich Nikulin

David H Woodmansee

Xiang-ju Gu

Wendy Richmond

Hank Michael Petrassi

Bao Nguyen

Gregory Chopiuk

The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds, and methods of using such compounds for treatment of joint damage or joint injury in a mammal, and for inducing differentiation of mesenchymal stem cells into chondrocytes.

Compounds and compositions for inducing chondrogenesis

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating joint damage or injury in a mammal, for inducing hyaline cartilage production or for inducing differentiation of chondrogenic progenitor cells into mature chondrocytes. 

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Ros, KDR, FMS, C-FMS, FLT3, c-Kit, JAK2, JAK3, Aurora, PDGFR, Lck, TrkA, TrkB, TrkC, IGF-IR, ALK4, ALK5 and ALK or combinations thereof.

Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors

The invention provides compounds having Formula Ia, or a pharmaceutically acceptable salt thereof, wherein R, R, R, Rand Y are as defined in the specification; as well as pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).

Compounds and compositions as inhibitors of cannabinoid receptor 1 activity

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the FAK, Abl, BCR-Abl, PDGF-R, c-Kit, NPM-ALK, Flt-3, JAK2 and c-Met kinases.

Substituted pyrrolo[2,3-2]pyrimidines as protein kinase inhibitors

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Bcr-Abl(T315I), ALK, BLK, BMX, BRK, C-kit, c-RAF, CSK, c-SRC, EGFR, Fes, FGFR3, Flt3, Fms, Fyn, IGF-1R, IR, JAK(2), JAK(3), KDR, Lck, NLK, p70S6K, PDGFR&#x3b1;, Ros, SAPK2&#x3b1;, SGK, SIK, Syk, Tie2 and TrkB kinases.

Compounds and compositions as protein kinase inhbitors

Growing community of inventors

San Diego, CA, United States of America

Ha-Soon Choi